Agreement with Framingham Pharma
15 December 2010 - 8:32PM
UK Regulatory
TIDMRGT
ReGen Signs Agreement with Framingham Pharma for the potential Distribution of
its Nutraceutical ColostrininTM in Argentina, Uruguay and Paraguay
15/12/2010
ReGen Therapeutics Plc ('ReGen' or the 'Company) announces that it has today
signed a Material Transfer Agreement (MTA) with Framingham Pharma of Argentina.
Framingham is the leading marketer of dietary supplements in Argentina. The
second largest market in South America, which is a growth area of the world
economy. Framingham reaches consumers across Argentina with a presence in all
pharmacies. It promotes its products through direct contact with health
professionals, participation in scientific events and significant media
activity. Framingham is a prestigious laboratory recognized by both health
professionals and the general public in Argentina. Framingham also has a
significant distribution capability in Uruguay and Paraguay with local partners.
Additional information is available on its corporate website
www.framinghampharma.com
Under the terms of this agreement ReGen will provide sufficient quantity of its
proprietary nutraceutical ingredient Colostrinin(TM) to allow Framingham to
develop a local formulation, initially for marketing in Argentina. If
successful this exercise will lead to the signing of a formal Licensing and
Distribution Agreement between the parties making Framingham the exclusive
distributor of Colostrinin(TM) in Argentina and other markets in the region.
No further details of the agreement will be disclosed at this time.
To date Colostrinin(TM) is marketed as a nutritional supplement to 'support
healthy brain aging and cognition in humans' in the US, Canada, Australia and
Poland under the brand name CogniSure(TM) *, in Cyprus under the brand name
Cognase(TM) **, in the UK under the brand name MemoryAid (TM) ***, in Turkey
under the brand name Dyna(TM) **** and in India under the brand name Cognate
(TM) *****
LG Life Sciences, Ltd ('LGLS') have also been appointed as the exclusive
distributor of ColostrininTM in South Korea subject to import and regulatory
approval being obtained******.
Following on from India, Turkey and S Korea the ReGen Board is delighted that
the Company has entered yet another growing market, which should lead to growth
in sales higher than in the older developed world.
* Colostrinin(TM) for use as a human nutraceutical is licensed in North
America and Australasia to Metagenics Inc. of San Clemente, California
(www.metagenics.com).
Colostrinin(TM) is distributed in Poland by Tagerr Polska, an
affliate of Tagerr a professional services and trading company established in
Köln, Germany. (www.cognisure.eu)
** Colostrinin(TM) is distributed in the Republic of Cyprus by Golgi
Pharmaceuticals Ltd (www.healthybrainaging.com).
*** Colostrinin(TM) is distributed in the UK by PRG Nutraceuticals Ltd
(www.memoryaid.com)
**** Colostrinin(TM) is distributed in Turkey by Eczacibasi Ilac Pazarlama
A.S (www.eczacibasi.com)
***** Colostrinin(TM) is distributed in India by USV Ltd (www.usvindia.com )
****** LG Life Sciences, South Korea (www.lgls.co.kr)
For further information:
Percy Lomax
ReGen Therapeutics Plc
Tel No 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel No 020 7628 3396
Nick Bealer/David Scott
Alexander David
Tel No 020 7448 9820
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: ReGen Therapeutics Plc via Thomson Reuters ONE
[HUG#1472690]
Argent Biopharma (LSE:RGT)
Historical Stock Chart
From May 2024 to Jun 2024
Argent Biopharma (LSE:RGT)
Historical Stock Chart
From Jun 2023 to Jun 2024